

Diaceutics PLC
("Diaceutics" or the "Company")

European international award win

Diaceutics PLC, (AIM: DXRX), the world's first diagnostic network provider for Precision Medicine, DXRX - The Diagnostic Network®, has won the International Star Award as part of the European Small and Mid Cap Awards 2020. The awards are a joint initiative of the European Commission, the Federation of European Securities Exchanges and European Issuers.

In June 2020, Diaceutics was recognised as 'IPO of the Year' at the 8th Annual Small Cap Awards, and was subsequently shortlisted for this International Star Award, alongside Proeduca Altus and Sanlorenzo, by an independent jury established by the European Commission.

Since admission to AIM in March 2019, Diaceutics has maintained its commitment to addressing key issues hindering cancer testing.

The International Star Award is presented to a newly listed mid-cap company that has demonstrated strategic growth internationally, defined by critical success factors such as international sales expansion, increased profitability and market share growth. Small and mid-cap companies are nominated for four separate categories which include International Star, Rising Star, Star of Innovation and Star of 2020.

The International Star Award win marks a significant period for Diaceutics, following the successful launch of DXRX - The Diagnostic Network® in October 2020. This platform is designed to improve the efficiency of cancer patient testing globally, reducing the current protracted timeline for a patient to secure optimal treatment from years to months.

Philip White, Diaceutics CFO said: *"I'd like to offer a sincere thanks to everyone involved in the European Small and Mid Cap Awards. It's a great honour for Diaceutics to be recognised with this International Star Award. This represents a seal of approval for the inroads we have made in recent years, particularly since our IPO. This award is really for our talented workforce, whose dedication and skill have driven this period of success for Diaceutics."*

"We will continue with our efforts to help reduce the significant lag in cancer testing and treatment. With the recent launch of DXRX, we are in a great position to make a significant impact in addressing the widespread inefficiencies in the cancer treatment landscape globally and help more patients receive the right drug at the right time."

For more information on DXRX - The Diagnostic Network® go to www.diaceutics.com

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
via Walbrook PR

Walbrook PR
Anna Dunphy
Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Mob: +44 (0)7876 741 001
Mob: +44 (0)7980 541 893

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world's first Network solution for the development and commercialization of precision medicine diagnostics. Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world's leading pharmaceutical companies. We have built the world's largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

NRADGBDBUBBDGGL